BioInvent International AB (publ) (BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors Transcript
…
2,106€
-3,97%
Echtzeit-Aktienkurs BIOINVENT INTERN. SK 2
Bid:
Ask: